Efficacy of Hepatitis B Vaccine Boosters Among Neonatally Vaccinated Children in Chongqing

Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Observational
SUMMARY

Worldwide, hepatitis B virus (HBV) infection is a major cause of acute hepatitis, and chronic infection with HBV often leads to chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. So far, the most effective way to prevent HBV infection in susceptible population is to inject hepatitis B vaccine. However, long-term protection against hepatitis B virus (HBV) after vaccination remains widely debated. This study aims to carry out a comprehensive study to evaluate the efficacy of hepatitis B vaccine booster from the aspect of humoral and cellular immunity in neonatally vaccinated children in Chongqing.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 1
Maximum Age: 15
Healthy Volunteers: t
View:

• Born after Jan. 1st, 2005 in Chongqing, China;

• Completion of the full primary immunization of HepB after birth;

• No HBV booster vaccine history.

Locations
Other Locations
China
Children's Hospital of Chongqing Medical University
RECRUITING
Chongqing
Contact Information
Primary
Yao Zhao, postdoctor
Zhaoy@cqmu.edu.cn
86-23-6360-3083
Time Frame
Start Date: 2021-07-09
Estimated Completion Date: 2025-12-31
Participants
Target number of participants: 80
Treatments
Hepatitis B vaccine booster
Children with anti-HBs at a level of\<10mIU/mL or \[10,100) mIU/mL before booster.
Observation
Children with anti-HBs at a level of \>100mIU/mL or \[10,100) mIU/mL before booster.
Sponsors
Leads: Children's Hospital of Chongqing Medical University

This content was sourced from clinicaltrials.gov